Jeffrey Paul Stonehouse

This inventor holds 8 USPTO granted patents and 3 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Astrazeneca Ab. Active years: 2010-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jeffrey Paul Stonehouse. Retrieved from https://idiyas.com/inventor/jeffrey-paul-stonehouse

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 (Patent Applications = 3)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 5.3

ph-index = 4

Forward Citations = 33(Granted Patents)

Location History:

Leicestershire, GB (2010 - 2013)
Macclesfield, GB (2014)
Cheshire, GB (2014)
Waltham, MA (US) (2017 - 2021)

Company Filing History:

8 out of 1,534

Astrazeneca Ab

patents

Years Active: 2010-2021

Loading Chart...

8 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11000525 - 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase (2021-05-11),

2. 10016430 - 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase (2018-07-10),

3. 9616063 - 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones as inhibitors of myeloperoxidase (2017-04-11),

4. 8748603 - Crystalline forms of N-[2-[[(2,3-difluorophenyl)methyl]THIO]-6-{[(1R,2S)-2,3-dihydroxy-1-methylpropyl]oxy}-4-pyrimidinyl]-1-azetidinesulfonamide (2014-06-10),

5. 8722883 - Pyrimidine sulphonamide derivatives as chemokine receptor modulators (2014-05-13),

6. 8410123 - Pyrimidine sulphonamide derivatives as chemokine receptor modulators (2013-04-02),

7. 8269002 - Pyrimidine sulphonamide derivatives as chemokine receptor modulators (2012-09-18),

8. 7838675 - Pyrimidine sulphonamide derivatives as chemokine receptor modulators (2010-11-23),

Title: **The Innovative Mind of Jeffrey Paul Stonehouse**

Introduction

Jeffrey Paul Stonehouse, an inventive genius based in Leicestershire, GB, has made significant contributions to the field of pharmaceuticals. With a portfolio of eight patents, his work showcases a commitment to addressing critical health issues through innovative solutions.

Latest Patents

Among his latest contributions, Stonehouse has developed compounds known as 1-[2-(aminomethyl)benzyl]-2-thioxo-1,2,3,5-tetrahydro-4H-pyrrolo[3,2-d]pyrimidin-4-ones. These compounds serve as inhibitors of myeloperoxidase (MPO), an enzyme implicated in various cardiovascular disorders. The formulations are designed not only for use in therapy but also promise a therapeutic approach to conditions such as heart failure and coronary artery disease. The ingenuity of Stonehouse’s work lies in the specific formula of these compounds, along with their potential for creating pharmaceutical innovations aimed at improving patient outcomes.

Career Highlights

Throughout his career, Stonehouse has been associated with AstraZeneca AB, a leading global pharmaceutical company. His work there emphasizes the vital intersection between innovative research and practical therapeutic applications, reinforcing the importance of intellectual property in fostering advancements in healthcare.

Collaborations

Collaborating alongside notable colleagues such as David R. Cheshire and Rhona Jane Cox, Stonehouse has been able to synergize ideas and propel research forward within his field. Their collective expertise highlights the collaborative nature of innovation in the pharmaceutical industry, enabling the development of groundbreaking therapies.

Conclusion

In summary, Jeffrey Paul Stonehouse stands out as a notable inventor in the pharmaceutical landscape. His eight patents, particularly in the realm of cardiovascular treatment, underline the significance of innovative approaches to enduring medical challenges. Through his collaborations at AstraZeneca AB, he continues to push the boundaries of science, benefitting patients and exemplifying the spirit of invention in modern medicine.

Profile summary based on public USPTO records.